Tenosynovial Giant Cell Tumors Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight

Tenosynovial Giant Cell Tumors Companies are Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others.
(Albany, USA) DelveInsight's "Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tenosynovial Giant Cell Tumors Market Forecast [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Tenosynovial Giant Cell Tumors Market Report:

* The Tenosynovial Giant Cell Tumors market size was valued approximately USD 300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In April 2024, SynOx Therapeutics secured USD 75 million in Series B funding. The raised capital will be allocated towards obtaining registrational Phase 3 clinical data and chemistry, manufacturing, and controls (CMC) data for emactuzumab, a monoclonal antibody (mAb) inhibiting CSF-1(R), intended for treating tenosynovial giant cell tumor (TGCT).
* In the seven major markets (7MM), localized tenosynovial giant cell tumor (TGCT) comprised approximately 80% of all TGCT cases in 2023.
* In the seven major markets (7MM), localized tenosynovial giant cell tumor (TGCT) was predominantly located in the digits, representing approximately 75% of all cases in 2023.
* Giant cell tumors can manifest in various joints such as the knee, ankle, and hip, depending on whether they are localized or diffuse. DelveInsight's estimates suggest that for diffuse TGCT, the highest tumor localization was observed in the knee, with approximately 30,000 cases in the United States in 2023.
* Despite the introduction of novel CSF1R inhibitors, the market size of off-label systemic therapies (such as imatinib, sunitinib, and others) is anticipated to exhibit stagnant growth in the forecast period. This is attributed to the rising prevalence of cases in the seven major markets (7MM).
* Key Tenosynovial Giant Cell Tumors Companies: Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others
* Key Tenosynovial Giant Cell Tumors Therapies: Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others
* The Tenosynovial Giant Cell Tumors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tenosynovial Giant Cell Tumors pipeline products will significantly revolutionize the Tenosynovial Giant Cell Tumors market dynamics.

Tenosynovial Giant Cell Tumors Overview

Tenosynovial giant cell tumors (TGCTs) are rare, benign, and typically slow-growing tumors that affect the synovium, tendon sheaths, or bursae within joints. These tumors are classified into two main types: localized TGCT (L-TGCT) and diffuse TGCT (D-TGCT), formerly known as pigmented villonodular synovitis (PVNS).

L-TGCT is more common, presenting as a well-circumscribed nodule, often in the hands or fingers. In contrast, D-TGCT involves large joints like the knee or hip and is more aggressive, causing widespread joint damage. Both types are associated with joint swelling, pain, stiffness, and restricted mobility.

The etiology of TGCT is not fully understood but is thought to involve chromosomal abnormalities and overexpression of colony-stimulating factor 1 (CSF1), which attracts macrophages and leads to tumor growth.

Diagnosis involves imaging such as MRI, which highlights the extent of the lesion, and biopsy for histological confirmation.

Treatment typically includes surgical removal, with arthroscopic techniques preferred for smaller tumors and open surgery for extensive cases. For recurrent or unresectable D-TGCT, targeted therapies like CSF1R inhibitors (e.g., pexidartinib) may be effective. Early detection and treatment are crucial to minimize joint damage and improve outcomes.

Get a Free sample for the Tenosynovial Giant Cell Tumors Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market [https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Tenosynovial Giant Cell Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Tenosynovial Giant Cell Tumors Epidemiology Segmentation:

The Tenosynovial Giant Cell Tumors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Tenosynovial Giant Cell Tumors
* Prevalent Cases of Tenosynovial Giant Cell Tumors by severity
* Gender-specific Prevalence of Tenosynovial Giant Cell Tumors
* Diagnosed Cases of Episodic and Chronic Tenosynovial Giant Cell Tumors

Download the report to understand which factors are driving Tenosynovial Giant Cell Tumors epidemiology trends @ Tenosynovial Giant Cell Tumors Epidemiology Forecast [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Tenosynovial Giant Cell Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to get launched during the study period. The analysis covers Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tenosynovial Giant Cell Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Tenosynovial Giant Cell Tumors Therapies and Key Companies

* Pexidartinib: Daiichi Sankyo Co., Ltd.
* vimseltinib: Deciphera Pharmaceuticals
* Pimicotinib(ABSK021): Abbisko Therapeutics
* AMB-05X: AmMax Bio, Inc.
* Emactuzumab: SynOx Therapeutics Limited
* Pimicotinib(ABSK021): Abbisko Therapeutics
* FPA008: Five Prime Therapeutics
* MCS110: Novartis

Discover more about therapies set to grab major Tenosynovial Giant Cell Tumors market share @ Tenosynovial Giant Cell Tumors Treatment Landscape [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Tenosynovial Giant Cell Tumors Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Tenosynovial Giant Cell Tumors Companies: Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others
* Key Tenosynovial Giant Cell Tumors Therapies: Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others
* Tenosynovial Giant Cell Tumors Therapeutic Assessment: Tenosynovial Giant Cell Tumors current marketed and Tenosynovial Giant Cell Tumors emerging therapies
* Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors market drivers and Tenosynovial Giant Cell Tumors market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Tenosynovial Giant Cell Tumors Unmet Needs, KOL's views, Analyst's views, Tenosynovial Giant Cell Tumors Market Access and Reimbursement

To know more about Tenosynovial Giant Cell Tumors companies working in the treatment market, visit @ Tenosynovial Giant Cell Tumors Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Tenosynovial Giant Cell Tumors Market Report Introduction

2. Executive Summary for Tenosynovial Giant Cell Tumors

3. SWOT analysis of Tenosynovial Giant Cell Tumors

4. Tenosynovial Giant Cell Tumors Patient Share (%) Overview at a Glance

5. Tenosynovial Giant Cell Tumors Market Overview at a Glance

6. Tenosynovial Giant Cell Tumors Disease Background and Overview

7. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Tenosynovial Giant Cell Tumors

9. Tenosynovial Giant Cell Tumors Current Treatment and Medical Practices

10. Tenosynovial Giant Cell Tumors Unmet Needs

11. Tenosynovial Giant Cell Tumors Emerging Therapies

12. Tenosynovial Giant Cell Tumors Market Outlook

13. Country-Wise Tenosynovial Giant Cell Tumors Market Analysis (2020-2034)

14. Tenosynovial Giant Cell Tumors Market Access and Reimbursement of Therapies

15. Tenosynovial Giant Cell Tumors Market Drivers

16. Tenosynovial Giant Cell Tumors Market Barriers

17. Tenosynovial Giant Cell Tumors Appendix

18. Tenosynovial Giant Cell Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tenosynovial-giant-cell-tumors-treatment-market-2034-ema-pdma-fda-approval-clinical-trials-epidemiology-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services



This release was published on openPR.